MOMELOTINIB AND CITARINOSTAT: CO-TARGETING JAK2/STAT3 AND HDAC6 IN LYMPHOID MALIGNANCIES, A NEW POTENTIAL THERAPEUTIC COMBINATION

被引：0
|
作者：
Cosenza, M. [1 ]
Civallero, M. [1 ]
Sacchi, S. [1 ]
Pozzi, S. [1 ]
机构：
[1] Univ Modena & Reggio Emilia, Dipartimento Med Diagnost Clin & Sanita Pubbl, Modena, Italy
来源：
HAEMATOLOGICA | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO105
引用
收藏
页码：S118 / S119
页数：2
相关论文
共 50 条
  • [1] Momelotinib and Citarinostat: Co-Targeting JAK2/STAT3 and HDAC6 in Lymphoid Malignancies, a New Potential Therapeutic Combination
    Cosenza, Maria
    Civallero, Monica
    Sacchi, Stefano
    Pozzi, Samantha
    BLOOD, 2017, 130
  • [2] Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6
    Cosenza, Maria
    Civallero, Monica
    Sacchi, Stefano
    Pozzi, Samantha
    BLOOD, 2018, 132
  • [3] Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination
    Cosenza, Maria
    Civallero, Monica
    Marcheselli, Luigi
    Sacchi, Stefano
    Pozzi, Samantha
    APOPTOSIS, 2020, 25 (5-6) : 370 - 387
  • [4] Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination
    Maria Cosenza
    Monica Civallero
    Luigi Marcheselli
    Stefano Sacchi
    Samantha Pozzi
    Apoptosis, 2020, 25 : 370 - 387
  • [5] JAK2/STAT3 activity in inflammatory breast cancer supports the investigation of JAK2 therapeutic targeting
    Overmoyer, B. A.
    Almendro, V.
    Shu, S.
    Peluffo, G.
    Park, S. Y.
    Nakhlis, F.
    Bellon, J. R.
    Yeh, E. D.
    Jacene, H. A.
    Hirshfield-Bartek, J.
    Polyak, K.
    CANCER RESEARCH, 2012, 72
  • [6] Sustained hyperactivated mTOR & JAK2/STAT3 pathways in inflammatory breast cancer (IBC): Evidence for mTOR plus JAK2 therapeutic targeting
    Jhaveri, K.
    Teplinsky, E.
    Arzu, R.
    Giashuddin, S.
    Sarfraz, Y.
    Alexander, M.
    Darvishian, F.
    Silvera, D.
    Levine, P. H.
    Hashmi, S.
    Hoffman, H. J.
    Paul, L.
    Singh, B.
    Goldberg, J. D.
    Hochman, T.
    Formenti, S.
    Valeta, A.
    Moran, M. S.
    Schneider, R. J.
    CANCER RESEARCH, 2013, 73
  • [7] JAK2/STAT3 as a new potential target to manage neurodegenerative diseases: An interactive review
    Panda, Siva Prasad
    Kesharwani, Adarsh
    Datta, Samaresh
    Prasanth, D. S. N. B. K.
    Panda, Sunil Kumar
    Guru, Ajay
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 970
  • [8] Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer
    Long, Lin
    Fei, Xiangyu
    Chen, Liucui
    Yao, Liang
    Lei, Xiaoyong
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [9] Sorghum polyphenol suppresses the growth as well as metastasis of colon cancer xenografts through co-targeting jak2/STAT3 and PI3K/Akt/mTOR pathways
    Darvin, Pramod
    Joung, Youn Hee
    Nipin, S. P.
    Kang, Dong Young
    Byun, Hyo Joo
    Hwang, Dae Yong
    Cho, Kwang Hyun
    Park, Kyung Do
    Lee, Hak Kyo
    Yang, Young Mok
    JOURNAL OF FUNCTIONAL FOODS, 2015, 15 : 193 - 206
  • [10] Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer
    Chaoqun Liu
    Zhihua Pan
    Qian Chen
    Zetao Chen
    Weiwei Liu
    Ling Wu
    Muhong Jiang
    Wandie Lin
    Yujie Zhang
    Weihao Lin
    Rui Zhou
    Liang Zhao
    Journal of Experimental & Clinical Cancer Research, 40
12345